Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-10

Clinical Trial Update: Efficacy and Safety of AGN-199201 in Patients With Persistent Erythema Associated With Rosacea [Phase 3]

View source ↗

Summary

Phase 3 trial update on AGN-199201 for persistent erythema associated with rosacea reports efficacy and safety outcomes.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • AGN-199201

Snippet

Sponsor: Allergan | Conditions: Erythema, Rosacea | Phase 3 | Status: COMPLETED | Results posted: 2016-03-10